Screening for prostate cancer is neither appropriate nor cost-effective.
The controversy surrounding prostate cancer screening stems in part from the different perspectives of health care policy analysts, practicing clinicians, patients, health insurers, and government agencies.
There is debate about whether sufficient experimental evidence exists to support the theory that early detection and treatment substantially lowers the associated morbidity and mortality.
From a societal perspective, the health gains that might result from prostate cancer screening are too uncertain to justify the substantial associated costs and adverse health effects ; therefore, it is neither appropriate nor cost-effective.
Mots-clés Pascal : Tumeur maligne, Prostate, Mâle, Dépistage, Homme, Politique sanitaire, Lésion focale, Rapport coût bénéfice, Epidémiologie, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Malignant tumor, Prostate, Male, Medical screening, Human, Health policy, Focal lesion, Cost benefit ratio, Epidemiology, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0057344
Code Inist : 002B14D02. Création : 21/05/1997.